A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ivermectin in asymptomatic and mild severity COVID-19 patients

Lakatos et al., EudraCT 2021-000166-15, Sep 2023
Progression 62% improvement lower risk ← → higher risk Ivermectin  Lakatos et al.  EARLY TREATMENT RCT Is early treatment with ivermectin beneficial for COVID-19? Double-blind RCT 10 patients in Hungary Trial underpowered to detect differences c19early.org Lakatos et al., EudraCT 2021-000166-15, Sep 2023 0 0.5 1 1.5 2+ RR
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 106 studies, recognized in 24 countries.
Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
6,600+ studies for 220+ treatments. c19early.org
Meta-analysis
Early terminated RCT with only 10 patients, reporting only COVID-19 progression.
This study is excluded in the after exclusion results of meta-analysis: minimal details provided.
Important missing comments or errors? Let us know.
risk of progression, 62.5% lower, RR 0.38, p = 1.00, treatment 0 of 4 (0.0%), control 1 of 6 (16.7%), NNT 6.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lakatos et al., 15 Sep 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Hungary, peer-reviewed, 2 authors, dosage 15mg days 1-4.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org May 2026 Hungary Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Nepal China Uzbekistan Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea Saudi Arabia Algeria Morocco Yemen Poland India Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Zambia Bolivia Fiji Bosnia-Herzegovina Jordan Georgia Switzerland Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Trinidad and Tobago Mongolia Czechia Israel Belarus North Macedonia Hong Kong Qatar Panama Serbia CAR Syria Hungary favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org May 2026 Hungary Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Nepal China Uzbekistan Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea Saudi Arabia Algeria Morocco Yemen Poland India Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Zambia Bolivia Fiji Jordan Georgia Switzerland Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore Iceland New Zealand Mongolia Czechia Israel Belarus North Macedonia Hong Kong Qatar Panama Serbia CAR Hungary favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0